Batu Biologics Issues Shareholder Update on Upcoming Milestones for 2016
January 26, 2016 at 12:46 PM EST
On behalf of Batu Biologics, I am pleased to provide you with a year-end update recapping our progress in 2015 and overviewing our plans for 2016.
Main accomplishments in the past year include:
With the help and support of our board, scientific advisors, investors, and collaborators, we are excited to pursue the following objectives for 2016.
I would like to thank you, our shareholders, for your unwavering support, which has allowed for the accelerated development of our novel cancer vaccine. I look forward to working closely with you in 2016 to bring our therapeutic candidates into the clinic and to substantially increase shareholder value.
Samuel C. Wagner
Safe Harbor Statement:
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Private Placement Memorandum. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.